Pyrukynd Commercialization Risk: The successful commercialization and market adoption of their lead product, Pyrukynd (mitapivat), for Pyruvate Kinase Deficiency (PKD) and its potential expansion into other indications like thalassemia and sickle cell disease, is critical and subject to market acceptance, physician prescription patterns, and patient adherence.

Clinical Trial Success and Regulatory Approval Risk: The success of their pipeline candidates in various rare genetic diseases hinges on favorable outcomes from ongoing and future clinical trials, and subsequently, on obtaining necessary regulatory approvals from agencies like the FDA, which are inherently uncertain, time-consuming, and costly.

Competition Risk: Despite focusing on rare diseases, Agios faces significant competition from other pharmaceutical and biotechnology companies developing alternative therapies, or existing treatments that could reduce the market opportunity for Pyrukynd and future pipeline assets.